Obstetric Liposomal Bupivacaine Via Surgical Transversus Abdominis Plane Block for Post Cesarean Pain Control

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 11, 2021

Primary Completion Date

August 31, 2022

Study Completion Date

October 13, 2022

Conditions
Cesarean Section ComplicationsPainOpioid Use
Interventions
DRUG

Liposomal bupivacaine

20 mL prior to closing fascia, the active drug (bupivacaine) is encapsulated in a liposomal platform and released slowly over the course of days with an approximate 72 hour duration.

DRUG

Bupivacaine Hydrochloride

30 mL bupivacaine hydrochloride 0.25 percent, local post-surgical anesthetic

OTHER

saline

post-surgical saline

Trial Locations (1)

53715

Unity-Point Health Meriter, Madison

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Meriter Foundation

OTHER

lead

University of Wisconsin, Madison

OTHER

NCT04897841 - Obstetric Liposomal Bupivacaine Via Surgical Transversus Abdominis Plane Block for Post Cesarean Pain Control | Biotech Hunter | Biotech Hunter